NFE2L2 and metabolic dysfunction-associated steatohepatitis: Interestingly, the expression of NOX4, which has two NFE2L2-binding AREs in its promoter (42), also increased in patients with NAFL or NASH with mild fibrosis but declined in those with NASH with significant/advanced fibrosis (Figure 1A).